Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 14/20 | 0.57 |
| ▸ | MAOB | P27338 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CALML3 | P27482 | 1/20 | 0.43 |
| ▸ | SDHA | P31040 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398457 | 0.86 | MAOA (0.59) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL3398134 | 0.86 | MAOB (0.57) | MAOAMAOBKCNH2F10LMNA | |
| SCHEMBL3398462 | 0.85 | MAOB (0.58) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL3398138 | 0.81 | MAOA (0.51) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL3392614 | 0.81 | MAOA (0.59) | MAOAMAOBKCNH2F10LMNA | |
| SCHEMBL5237076 | 0.80 | MAOA (0.73) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL3396973 | 0.80 | MAOA (0.60) | MAOAMAOBF10LMNAPTGS1 | |
| SCHEMBL13357945 | 0.79 | MAOA (0.63) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL13981045 | 0.79 | MAOA (0.59) | MAOAMAOBKCNH2CYP3A4CYP2D6 | |
| SCHEMBL5237704 | 0.77 | MAOA (0.70) | MAOAMAOBKCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-16 | — | — | US | disclosed |
| EP-2170874-A2 | NOVEL COMPOUNDS AND THEIR USE | Orchid Research Laboratories Limited (IN) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001192-A2 | NOVEL COMPOUNDS AND THEIR USE | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | HTRA1, PRSS1, PRNP | MAOA 2174/4885MAOB 2054/4885KCNH2 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.